(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) **International Patent Classification:**
C12Q 1/68 (2006.01)

(21) **International Application Number:**
PCT/GB2006/003661

(22) **International Filing Date:** 3 October 2006 (03.10.2006)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
0520235.3   5 October 2005 (05.10.2005)   GB

(71) **Applicant** *(for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, MK, ML, MN, MR, MW, MX, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC only)*: **ASTRAZENECA AB** [SE/SE]; S-SE-151 85 Södertälje (SE).

(71) **Applicant** *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **BENGTSSON, Olof** [SE/SE]; Astrazeneca R & D Mölndal, S-SE-431 83 Mölndal (SE). **BROWN, Ellen** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **CARLSSON, Stefan** [SE/SE]; Astrazeneca R & D Mölndal, S-SE-431 83 Mölndal (SE). **GIBSON, Neil, James** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **JAWAID, Ansar** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **KINDMARK, Andreas** [SE/SE]; Astrazeneca R & D Mölndal, S-SE-431 83 Mölndal (SE). **MARCH, Ruth, Eleanor** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) **Agent: GLOBAL INTELLECTUAL PROPERTY**; Astrazeneca Ab, S-SE-151 85 Södertälje (SE).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ,

(54) **Title:** ASSOCIATION BETWEEN HLA-DRB1* 07 ALLELE AND SUSCEPTIBILY TO INCREASED LEVELS OF ALAT FOLLOWING XIMELAGATRAN ADMINISTRATION

BoxPlot Of MaxALAT v DRB*0701

(57) **Abstract:** This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between HLA-DRB1*07 allele and susceptibility to increased levels of alanine aminotransferase (ALAT) following ximelagatran administration. Thus, this invention relates to methods for predicting susceptibility to elevated ALAT following ximelagatran administration and to methods for administering a pharmaceutically useful anticoagulant drug to certain suitable patients.

NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,

RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

ASSOCIATION BETWEEN HLA-DRB1*07 ALLELE AND SUSCEPTIBILY TO INCREASED LEVELS OF
ALAT FOLLOWING XIMELAGATRAN ADMINISTRATION ————————————————

Field of the Invention

This invention relates to a method for administering a pharmaceutically useful

5   anticoagulant drug to certain suitable patients and a method for identifying those patients

suitable for receiving the drug. The inventors have found an association between the

existence of the HLA-DRB1*07 allele and elevated ALAT following ximelagatran

administration. This association also exists with genetic markers that predict the presence

of the HLA-DRB1*07 allele, such as the HLA-DQA1*02 allele and three specific single

10   nucleotide polymorphisms close to the human DRB-1 gene. Thus, in particular, this

invention relates to a method for administering a pharmaceutically useful anticoagulant

drug to certain suitable patients and a method for identifying those patients suitable for

receiving the drug.

Background

15   Blood coagulation is the key process involved in both haemostasis (i.e. the

prevention of blood loss from a damaged vessel) and thrombosis (i.e. the formation of a

blood clot in a blood vessel, sometimes leading to vessel obstruction).

Coagulation is the result of a complex series of enzymatic reactions. One of the

ultimate steps in this series of reactions is the conversion of the proenzyme prothrombin to

20   the active enzyme thrombin.

Thrombin is known to play a central role in coagulation. It activates platelets,

leading to platelet aggregation, converts fibrinogen into fibrin monomers, which

polymerise spontaneously into fibrin polymers, and activates factor XIII, which in turn

crosslinks the polymers to form insoluble fibrin. Furthermore, thrombin activates factor V

25   and factor VIII leading to a "positive feedback" generation of thrombin from prothrombin.

By inhibiting the aggregation of platelets and the formation and crosslinking of

fibrin, effective inhibitors of thrombin would therefore be expected to exhibit

antithrombotic activity. In addition, antithrombotic activity would be expected to be

enhanced by effective inhibition of the positive feedback mechanism.

30   The development of low molecular weight inhibitors of thrombin has been

described by Claesson (Blood Coagul. Fibrin. 5:411, 1994), and certain thrombin inhibitors

based on peptide derivatives have been disclosed, for example, in European Patent

-2-

Application 0 669 317 and International Patent Applications WO 95/23609, WO 95/35309, WO 96/25426 and WO 94/29336.

The latter application discloses the peptide derivatives $R^aOOC\text{-}CH_2\text{-}(R)Cgl\text{-}Aze\text{-}Pab\text{-}H$, wherein R^a represents H, benzyl or C_{1-6} alkyl. When R^a represents H the

5 compound is known as melagatran.

The compound known as ximelagatran ($EtOOC\text{-}CH_2\text{-}(R)Cgl\text{-}Aze\text{-}Pab\text{-}OH$) has been developed for use, for example, in orthopaedic surgery and in atrial fibrillation. Upon oral administration ximelagatran is metabolised to the active thrombin inhibitor melagatran. Further details on ximelagatran and its preparation are contained in, for

10 example, WO 97/23499.

For reference, Aze = S-Azetidine-2-carboxylic acid; Cgl = cyclohexylglycine; H-Pab-H = 1-amidino-4-aminomethyl benzene; Pab-OH = 4-aminomethyl-benzamidoxime (4-aminomethyl-1-(amino-hydroxyiminomethyl)benzene).

Phase III clinical trials have been performed using fixed doses of melagatran and

15 ximelagatran for the prevention of VTE in hip or knee replacement surgery. In addition, clinical trials have been performed using ximelagatran for the treatment and long-term secondary prevention of VTE, and for the prevention of stroke in patients with non-valvular atrial fibrillation. Ximelagatran has also been tested for secondary thrombosis prophylaxis post-myocardial infarction/acute coronary syndrome (ACS).

20   Alanine aminotransferase (ALAT) is an enzyme mostly expressed in the liver (EC 2.6.1.2). It is also called serum glutamate pyruvate transaminase (SGPT) or alanine transaminase (ALT). This enzyme is released into the plasma by liver cell death, which is a normal event. However, when liver cell death increases, ALAT levels rise above the normal range. The spill-over of this enzyme into blood is routinely measured as a marker

25 of abnormal liver-cell damage. For example, alcoholic or viral hepatitis will increase ALAT levels, as will severe congestive heart failure. An elevated ALAT in the presence of normal levels of plasma alkaline phosphatase helps distinguish liver disease caused by liver-cell damage from diseases caused by problems in biliary ducts.

Elevations of ALAT are normally measured in multiples of the upper limit of

30 normal (ULN), with a reference range of 15-45 U/L in most laboratories. In 1987, in a study of 19,877 healthy Air Force recruits, only 99 (0.5%) had confirmed ALAT elevations (as reviewed in Green & Flamm (2002) Gastroenterology 123:1367–1384).

-3-

ALAT is markedly raised in hepatitis and other acute liver damage. The enzyme aspartate transaminase (AST) has a similar role, but this enzyme tends to be found in other tissues, such as the heart, so is not as specific to the liver.

During longer-term treatment with ximelagatran (>35 days) 7.9% of patients exhibited levels of alanine aminotransferase (ALAT) 3-fold or more above the upper limit of normal ($\geq$3xULN), compared with 1.2% in the comparator groups. The increase in ALAT values with ximelagatran usually occurred within the first 6 months of treatment and were mainly asymptomatic. Furthermore, these increases in ALAT were reversible in most patients regardless of whether treatment was continued or discontinued. Subject to the future regulatory approval of ximelagatran, regular liver function testing (LFT) using an appropriate algorithm may be required if ximelagatran is used for treatment periods exceeding a month. Studies are currently ongoing to try and establish the mechanism of the ALAT elevations, and their hepatic and overall clinical significance.

Accordingly, it is desirable to identify which patients are likely to experience raised ALAT levels when receiving ximelagatran. The identification of biomarkers of drug efficacy or safety, can be used to design diagnostic or prognostic tests.

The invention also relates to methods and materials for stratifying patients to be treated with ximelagatran into those that are at high or low likelihood of experiencing elevated ALAT levels following ximelagatran treatment, thus offering the ability to make informed decisions about whether or not a particular patient or sub-patient population should be treated with the drug.

The sub-groups of individuals identified as having increased or decreased likelihood of experiencing elevated ALAT following ximelagatran administration, can be used, inter alia, for targeted clinical trial programs and possibly also pharmacogenetic therapies.

By elevated ALAT we mean, for example $\geq$3-fold upper limit of normal (as reviewed in Green & Flamm, ibid).

The present invention is based on the finding of an association between HLA DRB1*07 alleles and raised ($\geq$3xULN) ALAT levels following ximelagatran treatment.

The HLA-DRB1 gene is part of the major histocompatibility complex (MHC), which was first identified in mice by Peter Gorer in 1936. In the 1950s and 1960s, studies of human leukocyte antigens, particularly by Dausset, Payne and van Rood, first identified

-4-

the human homologue of the mouse MHC, now known as the human leucocyte antigen (HLA) complex and demonstrated its major role in transplant survival (reviewed by Sharz & Shreffler, in Clinical Immunology, ed. Parker, W. B. Saunders Company (1980)).

HLA-DRB1 belongs to the HLA class II beta chain paralogues located on human
5   chromosome 6. The class II molecule is a heterodimer consisting of an alpha (DRA) and a beta chain (DRB), both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The beta chain is approximately 26-28 kDa. It is encoded by 6 exons, exon one encodes the
10   leader peptide, exons 2 and 3 encode the two extracellular domains, exon 4 encodes the transmembrane domain and exon 5 encodes the cytoplasmic tail. Within the DR molecule the beta chain contains all the polymorphisms specifying the peptide binding specificities. Hundreds of DRB1 alleles have been described and typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. DRB1 is present in all
15   individuals.

The HLA antigens were first detected using microcytoxicity assays in which sera could be tested against lymphocytes. Originally each laboratory working in the HLA system used its own nomenclature, and it was not until a World Health Organization (WHO) nomenclature committee was convened (1967) that common terms were agreed.
20   At this time antigens in the HLA-D or DR locus were detected by cellular and serological methods. Examples of alternative names for the antigen DR7 were DRw7, Dw7, UK7, FT1, etc. (Bodmer, British Medical Bulletin 34, 233-240 (1978)).

HLA nomenclature was further standardised in 2002 (Marsh *et al*, Human Immunology, 63, 1213-1268 (2002)). According to this nomenclature, the so-called low-
25   resolution type or two-number code (in this case HLA-DRB1*07) corresponds to all the alleles that encode the DR7 antigen. The four-number codes (HLA-DRB1*0701, 0703, 0704 etc.) refer to specific DRB1*07 alleles.

The first sequence of DRB1*07 was published in 1986 (Gergersen *et al*. Proc. Natl. Acad. Sci. U.S.A. 83:9149-9153, 1986) and referred to as DR7. Gregersen et al noted that
30   nucleotide sequence in the first domain of the HLA-DR beta chains diverged up to 11% between DR4, DR7 and DR9 haplotypes and that most of this variation resulted in productive amino acid changes (Gregersen et al, *ibid*). Young et al., sequenced

-5-

DRB1*0701 from the cell line MANN, homozygous for HLA region genes and
serologically identified as DR7, DRw53, DQw2, DP1 (Young *et al.* Proc. Natl. Acad. Sci.
U.S.A. 84:4929-4933, 1987). (EMBL Accession number: HS09201; SEQ ID NO: 1,
herein). A number of other DRB1*07 alleles (also known as subtypes) are now known

5   (reviewed in Schreuder *et al*, Human Immunology 66:170–210, 2005).

The reported frequency of DRB1*07 ranges from 27% in the Basque population
(Comas, D., et al. *Annals of Human Genetics*, 62, 123, 1998) to zero in the Nuba
population of Sudan and the Hoton population in Mongolia (Clayton et al. In: *Genetic
Diversity of HLA: Functional and Medical Implications* (ed. by D. Charron), Vol. 1, p.

10   665. EDK, Paris , 1997). The frequency in two Japanese populations was reported as 0.2%
and 0.4% (Lin et al., *Tissue Antigens*, 50:507, 1997; and Wang et al., *Tissue Antigens*,
41:223. 1993). The average frequency in North European populations (Norwegian,
German, and Polish) was reported as 12% (reviewed in Gilbert and Sanchez-Masaz,
European Journal of Immunogenetics 30, 361–374, 2003). Interestingly, this distribution

15   mirrors the frequency of cases of ximelagatran induced raised ALAT in North Europeans
as opposed to Asians observed by the inventors.

The use of knowledge of polymorphisms to help identify patients most suited to
therapy with particular pharmaceutical agents is often termed "pharmacogenetics".
Pharmacogenetics can also be used in pharmaceutical research to assist the drug selection

20   process. Polymorphisms are used in mapping the human genome and to elucidate the
genetic component of diseases. The reader is directed to the following references for
background details on pharmacogenetics and other uses of polymorphism detection:
Linder *et al.* (1997), Clinical Chemistry, 43:254; Marshall (1997), Nature Biotechnology.
15:1249; International Patent Application WO 97/40462, Spectra Biomedical; and Schafer

25   *et al*, (1998), Nature Biotechnology. 16:33.

Clinical trials have shown that patient response to treatment with pharmaceuticals
is often heterogeneous. Thus, there is a need for improved approaches to pharmaceutical
agent design and therapy. Furthermore, there may be opportunities for clinical trial patient
selection.

30   **Disclosure of the Invention**

According to a first aspect of the invention there is provided a method of
determining an individual's likelihood of experiencing elevated ALAT levels following

-6-

ximelagatran administration, comprising determining the HLA-DRB1*07 status of the individual, and assessing the likelihood according to whether or not the individual has an HLA-DRB1*07 allele.

The HLA-DRB1*07 status simply means determining whether the individual has
5   none, one or two copies of the HLA-DRB1*07 allele. This can be determined by various methodologies known to the person skilled in the art. These include, for example, serological or immunological methods to detect the presence of the DR7 antigen or molecular biological techniques to determine the nucleic acid sequence corresponding to the HLA-DRB1*07 alleles (e.g. SEQ ID NO: 1, or a subtype sequence thereof).

10   In one embodiment, the HLA-DRB1*07 status is determined by detection of the HLA-DRB1*07 allele on one or both copies of the chromosome 6, via nucleic acid determination, in a sample that has previously been removed from the individual.

According to another aspect of the invention there is provided a method for screening an individual for a genetic predisposition to release elevated ALAT from the
15   liver following ximelagatran administration, comprising analysing the individual's nucleic acid in a sample removed from the individual for the presence or absence of an HLA-DRB1*07 allele, and determining the status of the human by reference to the presence or absence or one of both possible copies of an HLA-DRB1*07 allele.

According to another aspect of the invention there is provided a method of determining
20   whether or not a patient in need of treatment with ximelagatran has a genetic makeup indicative of subjects likely to exhibit elevated ALAT following ximelagatran treatment, the method comprising:

(a) determining whether or not the patient's genome has an HLA-DRB1*07 allele; and,

(b) if the patient's genome has one or both copies of an HLA-DRB1*07 allele
25   identifying that patient as one at increased likelihood of exhibiting elevated ALAT following ximelagatran treatment.

In one embodiment of the invention the HLA-DRB1*07 allele determination is based on detection of the presence of the sequence disclosed in SEQID NO: 1, or a sequence that encodes a polypeptide with up to 4 amino acid differences provided the encoded allele
30   retains the same antigenic or binding specificity or function as that encoded by SEQ ID NO: 1.

-7-

In alternate embodiments of this aspect the HLA-DRB1*07 allele determination is based on detection of the presence of a sequence with up to 3 or up to 2, or up to 1 encoded amino acid differences provided the encoded allele retains the same antigenic or binding specificity or function as that encoded by SEQ ID NO: 1.

5   According to another aspect of the invention there is provided a method for screening an individual for a genetic predisposition to release elevated ALAT from the liver following ximelagatran administration, comprising detecting the presence or absence of the DR7 antigen in a sample removed from the individual, and determining the status of the human by reference to the presence or absence of the DR7 antigen. In certain

10   embodiments, detection of the DR7 antigen is carried out using cellular, serological or immunological techniques.

The HLA-DQA1 gene is also part of the major histocompatibility complex (MHC), and lies close (47kb) to HLA-DRB1 on human chromosome 6. It encodes the alpha chain of the HLA-DQ heterodimer and plays a similar role to HLA-DR in the

15   immune system by presenting peptides derived from extracellular proteins. Unlike the DR molecule, both the alpha chain and the beta chain of the DQ heterodimer are polymorphic and contain alleles that specify the peptide binding specificities of the molecule. Six common DQA1 alleles have been described. DQA1 is present in all individuals.

The inventors have also determined a statistically significant association between

20   the DQA1*02 allele (SEQ ID NO: 2; EMBL Accession number AY375912) and cases (patients with elevated ALAT levels), and that this allele predicts the presence of the DRB1*07 allele by virtue of its tight linkage disequilibrium with DRB1*07 (D' = 0.98). Thus, alleles of the DQ molecule that are in linkage disequilibrium with DRB1*07 alleles with D'> 0.9 also form part of this invention.

25   Single nucleotide polymorphisms (SNPs) represent one of the most common forms of genetic variation. These polymorphisms appear when a single nucleotide in the genome is altered (such as via substitution, addition or deletion). For example, if at a particular chromosomal location one member of a population has an adenine and another member has a thymine at the same position, then this position is a single nucleotide polymorphic

30   site. Each version of the sequence with respect to the polymorphic site is referred to as an "allele" of the polymorphic site. SNPs tend to be evolutionarily stable from generation to generation and, as such, can be used to study specific genetic abnormalities throughout a

-8-

population. If SNPs occur in the protein coding region it can lead to the expression of a variant, sometimes defective, form of the protein that may lead to development of a genetic disease. Such SNPs can therefore serve as effective indicators of the genetic disease. Some SNPs may occur in non-coding regions, but nevertheless, may result in differential

5   or defective splicing, or altered protein expression levels. SNPs can therefore be used as diagnostic tools for identifying individuals with a predisposition for certain diseases, genotyping the individual suffering from the disease in terms of the genetic causes underlying the condition, and facilitating drug development based on the insight revealed regarding the role of target proteins in the pathogenesis process.

10   The inventors have also determined a statistically significant association between SNPs close to the DRB1 gene (SNPs rs2858869, rs17426385 and rs9275141) and cases (patients with elevated ALAT levels), and that these polymorphisms are in linkage disequilibrium with DRB1*07 (D' = 0.85, 1.00 and 0.69 respectively). Thus, polymorphisms that are in linkage disequilibrium with DRB1*07 alleles with D'> 0.68

15   also form part of this invention.

             The presence of a G allele at position 101 of SEQ ID NO: 3 could also be used to optimise the benefit: risk ratio of an individual for ximelagatran treatment. Thus, the methods and kits of the invention can also be adapted or used for detecting the presence of rs2858869.

20   The presence of a C allele at position 101 of SEQ ID NO: 4 could also be used to optimise the benefit: risk ratio of an individual for ximelagatran treatment. Thus, the methods and kits of the invention can also be adapted or used for detecting the presence of rs17426385.

             The presence of a G allele at position 401 of SEQ ID NO: 5 could also be used to

25   optimise the benefit: risk ratio of an individual for ximelagatran treatment. Thus, the methods and kits of the invention can also be adapted or used for detecting the presence of rs9275141.

             The location of a polymorphisms can be precisely mapped by reference to published EMBL (or other sequence database) sequence accession numbers (i.e. see

30   above), alternatively, the person skilled in the art can precisely identify the location of the rs2858869, rs9275141 and rs9275141 polymorphisms close to the DRB1 gene simply by provision of flanking sequence adjacent the polymorphism sufficient to unambiguously

-9-

locate the polymorphism (e.g. position 101 of SEQ ID NO: 3, position 101 of SEQ ID NO: 4 or position 401 of SEQ ID NO: 5, herein). Provision of 10 or more nucleotides each side of the polymorphism should be sufficient to achieve precise location mapping of the particular polymorphism.

5   SEQ ID No: 3, derives from EMBL accession number AL662789. The SNP at position 101 being G is in reverse orientation.

SEQ ID No: 4, derives from EMBL accession number AY663414 . The SNP at position 101 being C is in forward orientation.

SEQ ID NO: 5, derives from EMBL accession number AY663413, The SNP at position

10   401 being G is in forward orientation.

Point mutations in polypeptides will be referred to as follows: natural amino acid (using 1 or 3 letter nomenclature), position, new amino acid. For (a hypothetical) example "D25K" or "Asp25Lys" means that at position 25 an aspartic acid (D) has been

15   changed to lysine (K). Multiple mutations in one polypeptide will be shown between square brackets with individual mutations separated by commas. The presence of a particular base at a polymorphism position will be represented by the base following the polymorphism position. For (a hypothetical) example, the presence of adenine at position 300 will be represented as: 300A.

20   According to another aspect of the invention there is provided a method for genotyping the DRB1 gene in a human individual comprising the steps of:

a) treating nucleic acid from a sample that has been removed from the individual so as to identify the nucleotides present corresponding to the *07 allelic sequences of the DRB1 gene, and

25   b) assigning the individual a particular genotype according to the nucleotides detected in step a).

According to another aspect of the invention there is provided a method of identifying a subtype of patients likely to experience elevated ALAT when treated with ximelagatran, comprising determining the HLA DRB-1*07 allele status of each patient,

30   and identifying patients that possess an DRB-1*07 allele as those that are likely to experience elevated ALAT when treated with ximelagatran.

-10-

The test sample (the nucleic acid containing sample) is conveniently a sample of blood, plasma, bronchoalveolar lavage fluid, saliva, sputum, cheek-swab or other body fluid or tissue (such as a biopsy sample) obtained from an individual that contain nucleic acid molecules. The nucleic acid containing sample that is to be analysed can either be a

5   treated or untreated biological sample isolated from the individual. A treated sample, may be for example, one in which the nucleic acid contained in the original biological sample has been isolated or purified from other components in the sample (tissues, cells, proteins etc), or one where the nucleic acid in the original sample has first been amplified, for example by polymerase chain reaction. Thus, it will be appreciated that the test sample

10   may equally be a nucleic acid sequence corresponding to the sequence in the test sample, that is to say that all or a part of the region in the sample nucleic acid may firstly be amplified using any convenient technique e.g. PCR, before analysis of allelic variation.

For the avoidance of doubt, the methods of the invention do not involve diagnosis practised on the human body. The methods of the invention are preferably conducted on a

15   sample that has previously been removed from the individual. The kits of the invention, however, may include means for extracting the sample from the individual.

When specifying a particular nucleotide at an allele position it is important to appreciate which of the two complementary strands of nucleic acid the nucleotide resides on. For example, a G on the positive strand will correspond to a C on the negative (reverse)

20   strand. The SNP alleles referred to herein, including the claims, are defined by the assays described in Table 1. For example, rs2858869 is on the reverse strand. The correct strand may also be deduced by the nucleotide sequence adjacent the allele, by reference to the sequence listings provided herein.

The ability to identify patients that have increased likelihood of experiencing elevated

25   ALAT following ximelagatran treatment allows the patient or their physician to assess their suitability for treatment with ximelagatran. It also allows, for example, the option to include or exclude such individuals in clinical studies.

According to another aspect of the invention there is provided a method for selecting subjects for inclusion in a clinical study of a therapeutic agent comprising:

30   (a) determining the HLA-DRB1*07 status of each subject;

         (b) grouping the individuals according to the heterozygous, homozygous positive or
              homozygous negative HLA-DRB1*07 status that each individual has; and,

-11-

(c) selecting subjects in one or more groups for inclusion in a clinical study of the
therapeutic agent.

In a particular embodiment, the therapeutic agent is ximelagatran. In another
embodiment, the homozygous negative subjects are included in a clinical study of

5   ximelagatran.

The presence of one or two copies of HLA-DRB1*07, however, does not mean that the
individual will experience elevated ALAT following ximelagatran treatment. It merely
suggests that the individual compared to the population as a whole has a higher likelihood
of experiencing elevated ALAT.

10   According to a further aspect of the invention there is provided a diagnostic or
prognostic method of predicting susceptibility to elevated ALAT following ximelagatran
administration, based on the detection of the presence or absence of HLA-DRB1*07, or a
polymorphism in linkage disequilibrium with a D'>0.8 therewith, in an individual.

According to a further aspect of the invention there is provided a diagnostic or

15   prognostic method of predicting susceptibility to elevated ALAT following ximelagatran
administration, based on the detection of the presence or absence of HLA-DRB1*07, or a
polymorphism in linkage disequilibrium with a D'>0.68 therewith, in an individual.

In a particular embodiment the polymorphism is in linkage disequilibrium with a
D'>0.8. In a further particular embodiment the polymorphism is in linkage disequilibrium

20   with a D'>0.9.

According to a further aspect of the invention there is provided a method of
predicting susceptibility to elevated ALAT following ximelagatran administration, in an
individual, comprising determining the presence or absence in a sample from said
individual of HLA-DRB1*07, or a polymorphism in linkage disequilibrium with a D'>0.68

25   therewith, wherein the presence of said allele or polymorphism is predictive of elevated
ALAT following ximelagatran administration.

In a particular embodiment the polymorphism is in linkage disequilibrium with a
D'>0.8. In a further particular embodiment the polymorphism is in linkage disequilibrium
with a D'>0.9.

30   In one embodiment, determination of the presence of HLA-DRB1*07 is based on
determination whether or not the individual has a sequence according to SEQ ID NO: 1.

-12-

In another embodiment of the invention, determination of the presence of HLA-DRB1*07 is based on determination whether or not the individual has a sequence according to SEQ ID NO: 2 (DQA1*02 allele).

In view of the statistically significant association between the G nucleotide at
5 rs2858869, the C nucleotide at rs17426385 or the G nucleotide at rs9275141 (positions 101, 101 or 401 of SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5, respectively), and elevated ALAT in patients on ximelagatran treatment, the methods, uses, kits and nucleic acids of the invention are equally applicable to determination of these SNPs on their own, or in conjunction with determination of HLA-DRB1*07 status.

10   Thus, according to another aspect of the invention there is provided a method of diagnosing or predicting susceptibility to elevated ALAT following ximelagatran administration in an individual, comprising determining the presence or absence in a sample removed from said individual of a guanine (G) nucleotide at rs2858869, a C nucleotide at rs17426385 or a G nucleotide at rs9275141 (positions 101, 101 or 401 of
15 SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5, respectively), wherein the presence of said nucleotide is diagnostic or predictive of susceptibility to elevated ALAT following ximelagatran administration. Clearly, as there are two complementary strands of nucleic acid, determination of G at position 101 of SEQ ID NO: 3, for example, could be carried out indirectly by determination of the presence of C on the complementary strand.

20   According to another aspect of the invention there is a provided a method for determining whether or not a patient to be treated with ximelagatran is likely to experience elevated ALAT, comprising determining the identity of nucleotides at rs2858869, rs17426385 or rs9275141 (positions 101, 101 or 401 SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5, respectively), wherein if the patient's genome comprises a G, C or G,
25 respectively at said position they are likely to experience elevated ALAT.

In another aspect the diagnostic or prognostic kits and methods of the invention involve detection of these SNPs as well as the presence of DQA1*02 and DRB1*07 (directly or indirectly).

The SNPs, DQA1*02 and DRB1*07 alleles of the invention demonstrate
30 significant association to experiencing elevated ALAT following ximelagatran administration. However, the person skilled in the art will appreciate that a diagnostic test consisting solely of the SNPs or allelic detection of the invention may not be diagnostic of

-13-

the occurrence of elevated ALAT following ximelagatran administration for any particular individual. Nevertheless, in line with future developments we envisage that the methods and kits of the present invention could form part of a panel of markers that in combination will be predictive of elevated ALAT following ximelagatran administration for an

5   individual, within normal clinical standards sufficient to influence clinical practice.

Because there are two copies of each chromosome (a maternal and paternal copy), at each chromosomal location the human may be homozygous for an allele or the human may be a heterozygote. If the individual is heterozygous the presence of both alternate polymorphisms will be present. With regard to HLA DRB1*07 status, persons with two

10   copies of this allele are referred to as homozygous positives, those with none are homozygous negatives and those with one copy are heterozygotes.

A wide variety of methods are available for determining the DRB1*07/ DR7 or DQA1*02 carrier status of an individual. The person skilled in the art is at liberty to choose any appropriate methodology. Representative examples of available methods

15   include:

1.   The AlleleSEQR DRB1 Typing kit (Atria Genetics, U.S.A.), distributed by Abbott Diagnostics. This method uses the Connexia Genomics Assign-SBT™ 3.2.7 software to call alleles. (Sayer DC *et al.* Tissue Antigens 63:412-23, 2004).

2.   Serological and molecular typing kits from Dynal Biotech, part of Invitrogen

20   Corporation, Carlsbad, California 92008, USA. Dynal kits that utilise SSP typing are available for both DR and DQ low resolution typing (Dynal AllSet+™ SSP kit). This technique uses Sequence Specific Primers for DNA based Tissue Typing. Each SSP kit consists of a panel of primer mixes that each contain a specific primer pair (i.e., the allele- and the group-specific primers) as well as a control primer pair that matches non-allelic

25   sequences present in all samples. This control acts as an internal PCR control to verify the efficiency of the PCR amplification.

3.   Pyrosequencing (Entz P *et al.* Tissue Antigens 65:67-80 (2005), Casamitjana N *et al.* Hum Immunol. 66:85-91, 2005).

4.   Sequence-specific primer (SSP)-PCR: Olerup O and Zetterquist H. (Tissue

30   Antigens 39: 225-235, 1992), Bunce M *et al.* Tissue Antigens 46: 355-367, 1995)

5.   Sequence specific oligonucleotide probe (SSOP) assay: (Fischer et al, Tissue Antigens 55:166-70, 2000).

-14-

6.   Serology (Dynal Biotech , Invitrogen Corporation, Carlsbad, California 92008,

USA, Biologische Analysensystem GmbH, D-35423 Lich, Germany, World Marrow

Donor Association Quality Assurance and IT Working Groups (Hum Immunol. 66:170-

210, 2005).

5   7.   Direct sequence analysis (e.g. dideoxy sequencing) for the sequence depicted in

SEQ ID NO: 1 for DRB1*07 detection, or SEQ ID NO: 2 for DQA1*02 detection, or a

sub-type variant sequence thereof that encodes a protein with the same specificity or

function thereof.

It will be apparent to the person skilled in the art that the sequence conferring the

10 specificity of HLA-DRB1*07 depends on the nucleotides of the hypervariable region in

exon 2 of the DRB1 gene (more than 95 nucleotides). Because of the hundreds of possible

alleles present in an individual in this region, sequencing or genotyping of all the

polymorphic residues within this exon may be necessary in order to assign the allelic status

of the individual. Analytical procedures that detect the high resolution or DRB1*07 alleles

15 of the individual (for example, HLA-DRB1*0701, 0703, 0704 etc) can also be used to

assign DRB1*07 status, since DRB1*07 status encompasses all these alleles. In addition,

analytical procedures that detect the presence of the DR7 antigen may also be used to

assign HLA-DRB1*07 status.

It will be apparent to the person skilled in the art that there are a large number of

20 analytical procedures, which may be used to detect the presence or absence of variant

nucleotides at one or more polymorphic positions of the invention. In general, the

detection of allelic variation requires a mutation discrimination technique, optionally an

amplification reaction and optionally a signal generation system. List 1 lists a number of

mutation detection techniques, some based on the PCR. These may be used in

25 combination with a number of signal generation systems, a selection of which are listed in

List 2. Further amplification techniques are listed in List 3. Many current methods for the

detection of allelic variation are reviewed by Nollau et al., Clin. Chem. 43, 1114-1120,

1997; and in standard textbooks, for example "Laboratory Protocols for Mutation

Detection", Ed. by U. Landegren, Oxford University Press, 1996 and "PCR", 2nd Edition

30 by Newton & Graham, BIOS Scientific Publishers Limited, 1997.

Abbreviations:

ALEX™	Amplification refractory mutation system linear extension
APEX	Arrayed primer extension
ARMS™	Amplification refractory mutation system
b-DNA	Branched DNA
Bp	base pair
CMC	Chemical mismatch cleavage
COPS	Competitive oligonucleotide priming system
DGGE	Denaturing gradient gel electrophoresis
ELISA	Enzyme Linked ImmunoSorbent Assay

FRET	Fluorescence resonance energy transfer
LCR	Ligase chain reaction
MASDA	Multiple allele specific diagnostic assay
NASBA	Nucleic acid sequence based amplification
OLA	Oligonucleotide ligation assay
PCR	Polymerase chain reaction
PTT	Protein truncation test
RFLP	Restriction fragment length polymorphism
SDA	Strand displacement amplification
SNP	Single nucleotide polymorphism
SSCP	Single-strand conformation polymorphism analysis
SSR	Self sustained replication
TGGE	Temperature gradient gel electrophoresis

List 1 - Mutation Detection Techniques

General: DNA sequencing, Sequencing by hybridisation

Scanning: PTT, SSCP, DGGE, TGGE, Cleavase, Heteroduplex analysis, CMC,
Enzymatic mismatch cleavage

-16-

Hybridisation Based

Solid phase hybridisation: Dot blots, MASDA, Reverse dot blots, Oligonucleotide arrays (DNA Chips).

Solution phase hybridisation: Taqman™ - US-5210015 & US-5487972 (Hoffmann-La

5   Roche), Molecular Beacons - Tyagi *et al* (1996), Nature Biotechnology, 14, 303; WO 95/13399 (Public Health Inst., New York)

Extension Based: ARMS™, ALEX™ - European Patent No. EP 332435 B1 (Zeneca Limited), COPS - Gibbs *et al* (1989), Nucleic Acids Research, 17, 2347.

Incorporation Based: Mini-sequencing, APEX

10   **Restriction Enzyme Based:** RFLP, Restriction site generating PCR

Ligation Based: OLA

Other: Invader assay

List 2 - Signal Generation or Detection Systems

15   **Fluorescence:** FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom Patent No. 2228998 (Zeneca Limited)

Other: Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry

20   List 3 - Further Amplification Methods

SSR, NASBA, LCR, SDA, b-DNA

List 4 - Protein variation detection methods

Immunoassay

25   Immunohistology

Peptide sequencing

In one embodiment, the presence or absence of a particular SNP or allele is determined using polymerase chain reaction (PCR). In a particular SNP discriminating

30   embodiment the PCR is performed with allele-specific oligonucleotide primers capable of discriminating between the different bases at a particular allele. Such as using amplification refractory mutation system (ARMS™-allele specific amplification). In a

-17-

further embodiment, the PCR is performed using one or more fluorescently labelled probes or using one or more probes which include a DNA minor groove binder. The presence or absence of a particular SNP allele can also be determined, for example, by sequence analysis.

5   The nucleic acid sequence method for diagnosis is preferably one which is determined by a method selected from amplification refractory mutation system, restriction fragment length polymorphism and primer extension. In another embodiment, the nucleotide present at each polymorphic position is determined by sequence analysis, such as by dideoxy sequencing.

10   Preferred mutation detection techniques include ARMS™-allele specific amplification, ALEX™, COPS, Taqman, Molecular Beacons, RFLP, and restriction site based PCR and FRET techniques. Immunoassay techniques are known in the art e.g. A Practical Guide to ELISA by D M Kemeny, Pergamon Press 1991; Principles and Practice of Immunoassay, 2nd edition, C P Price & D J Newman, 1997, published by Stockton Press

15   in USA & Canada and by Macmillan Reference in the United Kingdom.

        Particularly preferred methods include ARMS™-allele specific amplification, OLA and RFLP based methods. The allele specific amplification technique known in the art as ARMS™-allele specific amplification is an especially preferred method. ARMS™-allele specific amplification (described in European patent No. EP-B-332435,

20   US patent No. 5,595,890 and Newton et al. (Nucleic Acids Research, Vol. 17, p.2503; 1989)), relies on the complementarity of the 3' terminal nucleotide of the primer and its template. The 3' terminal nucleotide of the primer being either complementary or non-complementary to the specific mutation, allele or polymorphism to be detected. There is a selective advantage for primer extension from the primer whose 3' terminal nucleotide

25   complements the base mutation, allele or polymorphism. Those primers which have a 3' terminal mismatch with the template sequence severely inhibit or prevent enzymatic primer extension. Polymerase chain reaction or unidirectional primer extension reactions therefore result in product amplification when the 3' terminal nucleotide of the primer complements that of the template, but not, or at least not efficiently, when the 3' terminal

30   nucleotide does not complement that of the template.

        In a further diagnostic aspect of the invention the presence or absence of variant nucleotides is detected by reference to the loss or gain of, optionally engineered, sites

-18-

recognised by restriction enzymes. The person of ordinary skill will be able to design and implement diagnostic procedures based on the detection of restriction fragment length polymorphism due to the loss or gain of one or more of the restriction sites due to the presence of a polymorphism.

5   The invention further provides nucleotide primers, which detect the DRB1 gene polymorphisms of the invention. Such primers can be of any length, for example between 8 and 100 nucleotides in length, but will preferably be between 12 and 50 nucleotides in length, more preferable between 17 and 30 nucleotides in length.

According to another aspect of the present invention there is provided an allele

10   specific primer or probe capable of detecting whether or not the individual has a sequence according to SEQ ID NO: 2 (DQA1*02 allele), or whether the individual has a G nucleotide at rs2858869, a C nucleotide at rs17426385 or a G nucleotide at rs9275141 (positions 101, 101 or 401 of SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO:5, respectively)

15   An allele specific primer is used, generally together with a constant primer, in an amplification reaction such as a PCR reaction, which provides the discrimination between alleles through selective amplification of one allele at a particular sequence position e.g. as used for ARMS™-allele specific amplification assays. The allele specific primer is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably

20   about 17-30 nucleotides.

An allele specific primer preferably corresponds exactly with the allele to be detected but derivatives thereof are also contemplated wherein about 6-8 of the nucleotides at the 3' terminus correspond with the allele to be detected and wherein up to 10, such as up to 8, 6, 4, 2, or 1 of the remaining nucleotides may be varied without significantly

25   affecting the properties of the primer. Often the nucleotide at the -2 and/or -3 position (relative to the 3' terminus) is mismatched in order to optimise differential primer binding and preferential extension from the correct allele discriminatory primer only.

Primers may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for

30   Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1st Edition. If required the primer(s) may be labelled to facilitate detection.

-19-

The allele-specific oligonucleotide probe is preferably 17-50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

The design of such probes will be apparent to the molecular biologist of ordinary skill. Such probes are of any convenient length such as up to 50 bases, up to 40 bases,
5   more conveniently up to 30 bases in length, such as for example 8-25 or 8-15 bases in length. In general such probes will comprise base sequences entirely complementary to the corresponding wild type or variant locus in the gene. However, if required one or more mismatches may be introduced, provided that the discriminatory power of the oligonucleotide probe is not unduly affected. The probes of the invention may carry one or
10   more labels to facilitate detection, such as in Molecular Beacons. Single stranded oligonucleotides corresponding to the polymorphic base in SEQ ID NO: 3, 4 or 5 (positions 101, 101 or 401, respectively) or their complement, could be used as probes to detect the particular polymorphism at the central position. The probe would bind more efficiently to a target sequence that possessed the particular complementary polymorphism
15   base at this central (polymorphism) location than one with a base mismatch.

According to another aspect of the present invention there is provided an allele specific primer or an allele specific oligonucleotide probe capable of detecting the presence of HLA-DRB1*07 and/or HLA-DQA1*02, and/or any of the SNPs: rs2858869, rs17426385, or rs9275141, and its/their use in any of the methods of the present invention.

20   According to another aspect of the invention there is provided a kit for screening for a genetic predisposition to experience elevated ALAT following ximelagatran administration, which kit comprises:

(i)   reagents for detecting the presence of HLA-DRB1*07 or a polymorphism in linkage disequilibrium with D'>0.68 therewith, and optionally,

25   (ii)   means for collecting a biological sample.

In a particular embodiment the polymorphism is in linkage disequilibrium with a D'>0.8. In a further particular embodiment the polymorphism is in linkage disequilibrium with a D'>0.9.

In one embodiment the biological sample is a nucleic acid sample or nucleic acid
30   containing sample. In another embodiment the polymorphism in linkage disequilibrium with D'>0.68 to HLA-DRB1*07 allele is DQA1*02 or the SNPs rs2858869, rs17426385, or rs9275141.

-20-

In a particular embodiment the polymorphism is in linkage disequilibrium with a D'>0.8. In a further particular embodiment the polymorphism is in linkage disequilibrium with a D'>0.9.

According to another aspect of the invention there is provided an in vitro diagnostic
5   kit for determining the identity of the alleles DRB1*07, DQA1*02 or the SNPs rs2858869, rs17426385, or rs9275141 in the human DRB1 gene region, said kit comprising components for the determination of the nucleotides present at said gene locations.

In particular embodiments of the invention, the kit components for determining the said SNP include allele-specific amplification primers or allele-specific hybridisation
10   probes capable of determining the identity of the nucleotide base at the SNP location.

According to another aspect of the invention there is provided a kit comprising one or more diagnostic primer(s) and/or one or more allele-specific oligonucleotide probes(s) capable of determining the identity of the nucleotides present at DQA1*02 or any of the SNPs rs2858869, rs17426385, or rs9275141, or a polymorphism in linkage disequilibrium
15   with D'>0.68 therewith, in the human DRB1 gene region.

In a particular embodiment the polymorphism is in linkage disequilibrium with a D'>0.8. In a further particular embodiment the polymorphism is in linkage disequilibrium with a D'>0.9.

The diagnostic kits may comprise appropriate packaging and instructions for use in
20   the methods of the invention. Such kits may further comprise appropriate buffer(s) and polymerase(s) such as thermostable polymerases, for example taq polymerase. Such kits may also comprise companion primers and/or control primers or probes. A companion primer is one that is part of the pair of primers used to perform PCR. Such primer usually complements the template strand precisely.

25   According to another aspect of the invention there is provided the use of a diagnostic kit capable of determining an individuals' likelihood of experiencing elevated ALAT following ximelagatran administration, by haplotyping the DRB1 gene at at least two locations, at least one of which is rs2858869 or exon 2 of the DRB1 gene, for stratifying individuals into particular haplotype groups.

30   According to another aspect of the invention there is provided the use of a diagnostic kit capable of determining an individual's risk of experiencing elevated ALAT following ximelagatran administration, by haplotyping the DRB1 gene region at at least

-21-

two locations, at least one of which is the DQA1 gene or exon 2 of the DRB1 gene, for

stratifying individuals into particular haplotype groups.

One particular application of this is for selecting members from one or more of the

stratified groups for inclusion in a clinical trial to determine the efficacy of a drug. In a

5   particular embodiment, the clinical trial is measuring the efficacy of the drug at treating

atherosclerosis or an atherosclerosis mediated disease.According to another aspect of the

invention there is provided a method for selecting individuals for participation in a clinical

trial to assess the effect of ximelagatran administration on ALAT levels in an individual,

comprising:

10   a) individually genotyping the DRB1 gene for the presence of the DRB1*07 allele

from a nucleic acid containing sample already isolated from each individual;

b) grouping the individuals according to the particular genotype that each individual

belongs to, and

c) selecting individuals from one or more genotype groups for inclusion in the clinical

15   trial.

The genotype groups will be homozygous positive (individuals with 2 copies of

DRB1*07), heterozygous (individuals with one copy of DRB1*07) and homozygous

negative (individuals that lack a copy of DRB1*07).

The data generated from the methods and kits of the invention represent a valuable

20   information source with which to characterise individuals in terms of, for example, their

likelihood to experience elevated ALAT following ximelagatran administration. These

data may be stored in a computer readable medium. The alleles and particular

polymorphisms referred to herein are particularly useful as components in databases useful

for sequence identity, genome mapping, pharmacogenetics and other search analyses.

25   Generally, the sequence information relating to the nucleic acid sequences and

polymorphisms of the invention may be reduced to, converted into or stored in a tangible

medium, such as a computer disk, preferably in a computer readable form. For example,

chromatographic scan data or peak data, photographic scan or peak data, mass

spectrographic data, sequence gel (or other) data.

30   The computer readable medium may be used, for example, in homology searching,

mapping, haplotyping, genotyping or pharmacogenetic analysis. The computer readable

medium can be any composition of matter used to store information or data, including, for

-22-

example, floppy disks, tapes, chips, compact disks, digital disks, video disks, punch cards and hard drives.

The compounds of WO 94/29336 and the prodrug compounds of WO 97/23499 are expected to be useful in those conditions where inhibition of thrombin is required.

In particular, the compounds of WO 97/23499, and ximelagatran in particular, are thus indicated both in the therapeutic and/or prophylactic treatment of thrombosis and hypercoagulability in blood and tissues of animals including man.

It is known that hypercoagulability may lead to thrombo-embolic diseases. Thrombo-embolic diseases which may be mentioned include: activated protein C resistance, such as the factor V-mutation (factor V Leiden), and inherited or acquired deficiencies in antithrombin III, protein C, protein S, heparin cofactor II. Other conditions known to be associated with hypercoagulability and thrombo-embolic disease include circulating antiphospholipid antibodies (Lupus anticoagulant), homocysteinemi, heparin induced thrombocytopenia and defects in fibrinolysis. The compounds of WO 97/23499, and ximelagatran in particular, are thus indicated both in the therapeutic and/or prophylactic treatment of these conditions.

The compounds of WO 97/23499, and ximelagatran in particular, are further indicated in the treatment of conditions where there is an undesirable excess of thrombin without signs of hypercoagulability, for example in neurodegenerative diseases such as Alzheimer's disease.

Particular disease states which may be mentioned include: the therapeutic and/or prophylactic treatment of venous thrombosis and pulmonary embolism, arterial thrombosis (eg in myocardial infarction, unstable angina, thrombosis-based stroke and peripheral arterial thrombosis) and systemic embolism usually from the atrium during arterial fibrillation or from the left ventricle after transmural myocardial infarction.

Moreover, the compounds of WO 97/23499, and ximelagatran in particular, are expected to have utility in prophylaxis of re-occlusion (i.e. thrombosis) after thrombolysis, percutaneous trans-luminal angioplasty (PTA) and coronary bypass operations; the prevention of re-thrombosis after microsurgery and vascular surgery in general.

Further indications include the therapeutic and/or prophylactic treatment of disseminated intravascular coagulation caused by bacteria, multiple trauma, intoxication or any other mechanism; anticoagulant treatment when blood is in contact with foreign

-23-

surfaces in the body such as vascular grafts, vascular stents, vascular catheters, mechanical and biological prosthetic valves or any other medical device; and anticoagulant treatment when blood is in contact with medical devices outside the body such as during cardiovascular surgery using a heart-lung machine or in haemodialysis.

5   In addition to its effects on the coagulation process, thrombin is known to activate a large number of cells (such as neutrophils, fibroblasts, endothelial cells and smooth muscle cells). Therefore, the compounds of WO 97/23499, and ximelagatran in particular, may also be useful for the therapeutic and/or prophylactic treatment of idiopathic and adult respiratory distress syndrome, pulmonary fibrosis following treatment with radiation or

10   chemotherapy, septic shock, septicemia, inflammatory responses, which include, but are not limited to, edema, acute or chronic atherosclerosis such as coronary arterial disease, cerebral arterial disease, peripheral arterial disease, reperfusion damage, and restenosis after percutaneous trans-luminal angioplasty (PTA).

Compounds of WO 97/23499, and ximelagatran in particular, that lead to inhibition

15   of trypsin and/or thrombin may also be useful in the treatment of pancreatitis.

According to a further aspect of the present invention, there is provided a method of treatment of a condition where inhibition of thrombin is required which method comprises administration of a therapeutically effective amount of a compound of WO 97/23499, and ximelagatran in particular, or a pharmaceutically acceptable salt thereof, to a person

20   suffering from, or susceptible to such a condition, which person has been previously tested for the presence of an HLA-DRB1*07 allele. In a preferred embodiment, the treatment is applied to individuals that lack an HLA-DRB1*07 allele.

The compounds of WO 97/23499, and ximelagatran in particular, will normally be administered orally, buccally, rectally, dermally, nasally, tracheally, bronchially, by any

25   other parenteral route or via inhalation, in the form of pharmaceutical preparations comprising the prodrug either as a free base, or a pharmaceutical acceptable non-toxic organic or inorganic acid addition salt, in a pharmaceutically acceptable dosage form. Depending upon the disorder and patient to be treated and the route of administration, the compositions may be administered at varying doses.

30   The compounds of WO 97/23499, and ximelagatran in particular, may also be combined and/or co-administered with any antithrombotic agent with a different mechanism of action, such as the antiplatelet agents acetylsalicylic acid, ticlopidine,

-24-

clopidogrel, thromboxane receptor and/or synthetase inhibitors, fibrinogen receptor antagonists, prostacyclin mimetics and phosphodiesterase inhibitors and ADP-receptor (P$_2$T) antagonists.

The compounds of WO 97/23499, and ximelagatran in particular, may further be combined and/or co-administered with thrombolytics such as tissue plasminogen activator (natural or recombinant), streptokinase, urokinase, prourokinase, anisolated streptokinase plasminogen activator complex (ASPAC), animal salivary gland plasminogen activators, and the like, in the treatment of thrombotic diseases, in particular myocardial infarction.

According to a further aspect of WO 97/23499 there are provided suitable pharmaceutical formulations. Suitable daily doses of the compounds of WO 97/23499, and ximelagatran in particular (especially ximelagatran in a form disclosed in WO 00/14110), in therapeutical treatment of humans are about 0.001-100mg/kg body weight at peroral administration and 0.001-50mg/kg body weight at parenteral administration.

The compounds of WO 97/23499, and ximelagatran in particular, are inactive per se to thrombin, trypsin and other serine proteases. The compounds thus remain inactive in the gastrointestinal tract and the potential complications experienced by orally administered anticoagulants which are active *per se*, such as bleeding and indigestion resulting from inhibition of trypsin, may thus be avoided.

Furthermore, local bleeding associated with and after parenteral administration of an active thrombin inhibitor may be avoided by using the compounds of WO 97/23499, and ximelagatran in particular.

Thus, according to another aspect of the present invention there is provided a method of treating a human in need of treatment with ximelagatran, which the method comprises:

i)   determining the HLA DRB1*07 status of the human; and,

ii)   If the human does not possess DRB1*07, administering an effective amount of the drug ximelagatran.

According to another aspect of the present invention there is provided a method of treating a patient in need of anti-thrombotic treatment comprising:

(a) determining whether or not the patient possesses a copy of HLA-DRB1*07; and,

(b) if the patients does not possess at least one copy of HLA-DRB1*07, treating the patient with an anti- thrombotic agent.

-25-

In a particular embodiment of this aspect of the invention the anti-thrombotic agent is ximelagatran or melagatran.

According to another aspect of the invention there is a provided a method of recommending an anti-thrombotic treatment, the method comprising:

5   (a) selecting a patient in need of anti-thrombotic treatment whose genome has been identified as lacking HLA-DRB1*07; and

recommending that the patient be treated with ximelagatran or melagatran.

According to another aspect of the invention there is a provided a method of treatment comprising:

10   (a) selecting a patient in need of anti-thrombotic treatment, the patient's genome having been identified as lacking an HLA-DRB1*07; and

         (b) treating the patient with ximelagatran.

According to another aspect of the present invention there is provided a pharmaceutical pack comprising ximelagatran and instructions for administration of the

15   drug to humans diagnostically tested for HLA-DRB1*07.

According to another aspect of the invention there is a provided the use of ximelagatran in the manufacture of a medicament for treating patients in need of anti-thrombotic treatment and whose genomes lack one or both copies of HLA-DRB1*07.

According to another aspect of the present invention there is provided use of an

20   antibody capable of selectively binding to DR7 antigen for assessing an individual's likelihood of experiencing elevated ALAT following ximelagatran administration.

Antibodies can be prepared using any suitable method. For example, purified polypeptide may be utilized to prepare specific antibodies. The term "antibodies" is meant to include polyclonal antibodies, monoclonal antibodies, and the various types of antibody

25   constructs such as for example F(ab')$_2$, Fab and single chain Fv. Antibodies are defined to be specifically binding if they bind DR7 with a K$_a$ of greater than or equal to about 10^7 M^{-1}. Affinity of binding can be determined using conventional techniques, for example those described by Scatchard et al., *Ann. N.Y. Acad. Sci.*, (1949) 51:660.

Polyclonal antibodies can be readily generated from a variety of sources, for

30   example, horses, cows, goats, sheep, dogs, chickens, rabbits, mice or rats, using procedures that are well-known in the art. In general, antigen is administered to the host animal typically through parenteral injection. The immunogenicity of antigen may be enhanced

-26-

through the use of an adjuvant, for example, Freund's complete or incomplete adjuvant. Following booster immunizations, small samples of serum are collected and tested for reactivity to antigen. Examples of various assays useful for such determination include those described in: *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold

5   Spring Harbor Laboratory Press, 1988; as well as procedures such as countercurrent immuno-electrophoresis (CIEP), radioimmunoassay, radioimmunoprecipitation, enzyme-linked immuno-sorbent assays (ELISA), dot blot assays, and sandwich assays, see U.S. Patent Nos. 4,376,110 and 4,486,530.

       Monoclonal antibodies may be readily prepared using well-known procedures, see

10   for example, the procedures described in U.S. Patent Nos. RE 32,011; 4,902,614; 4,543,439 and 4,411,993; Monoclonal Antibodies, Hybridomas: *A New Dimension in Biological Analyses,* Plenum Press, Kennett, McKearn, and Bechtol (eds.), (1980).

       Monoclonal antibodies for use in the invention can be produced using alternative techniques, such as those described by Alting-Mees et al., "Monoclonal Antibody

15   Expression Libraries: A Rapid Alternative to Hybridomas", *Strategies in Molecular Biology* (1990) 3:1-9, which is incorporated herein by reference. Similarly, binding partners can be constructed using recombinant DNA techniques to incorporate the variable regions of a gene that encodes a specific binding antibody. Such a technique is described in Larrick et al., *Biotechnology*, (1989) 7: 394.

20   Once isolated and purified, the antibodies may be used to detect the presence of antigen in a sample using established assay protocols, see for example "A Practical Guide to ELISA" by D. M. Kemeny, Pergamon Press, Oxford, England.

       The invention will now be illustrated but not limited by reference to the following non-limiting examples and figure 1 which shows a Boxplot of maximum ALAT levels

25   against HLA DRB1* 0701 status.

EXAMPLE 1

       In summary, the present invention arose from an open, multicentre, retrospective pharmacogenetic case-control study seeking explanation of ximelagatran's

30   pharmacodynamic effects on transient liver enzymes during long-term treatment. The objective of the study was to retrospectively investigate whether elevated alanine

-27-

aminotransferase (ALAT) levels during long-term ximelagatran treatment are associated
with any specific genetic variations.

Subject population

Subjects who had a transient increase of ALAT ≥3x ULN and thereafter returned to the
5   baseline level at any time period during days 45-160 of treatment (cases) were compared
with subjects (controls) selected from the same studies but without ALAT increase during
this period.

In Phases 1 & 2, subjects were selected from males and females who had taken part
in one of the long-term treatment ximelagatran studies in the following indications:
10   prevention of stroke in atrial fibrillation; treatment of venous thromboembolism; long-term
secondary prevention after treatment of VTE; or, secondary prevention in acute coronary
syndromes.

In order to increase the statistical power of the analysis, 2 controls were selected for
each identified case. To minimise differences in environmental background and increase
15   the homogeneity of the genetic characteristics, the 2 controls were (as far as operationally
possible within each country) matched for weight, age, and sex and, if possible, were
chosen from the same investigational site as the corresponding case.

Potential control subjects were identified from the databases of the nominated
studies, to be matched for study, country, study site, sex, age, and weight. Where it was
20   not possible to match controls for all the above criteria, matching criteria were prioritised
as follows: country and study, sex (where possible), and site (where possible); the
difference between case and control age and weight were minimised such that the highest
priority controls had least difference between case and control. An algorithm was devised
to assign priorities to controls:
25   Priority = (ABS(100-(100*Control Age/Case Age))+ ABS(100-(100*Control weight/Case
weight)))/2

Since no clear relationship of ALAT elevation to ximelagatran dose had been
identified, it was decided not to match cases and controls for dose, but instead to use dose
as a covariate in the statistical model. By not including dose as a criterion for selecting
30   cases and controls, there was greater opportunity to match for other variables.

Subjects who had a transient increase of ALAT ≥3x ULN and thereafter returned to
the baseline level at any time period during days 45-160 of treatment (cases) were

-28-

compared with subjects (controls) selected from the same studies but without ALAT

increase during this period. In this analysis 74 cases and 169 controls were selected. Case-

control status was used as the primary variable for statistical analysis. Max ALAT and

AUC in the treatment interval 0-180 days were used for quantitative trait association

5   analysis.

       A single blood sample with informed consent was obtained from each of the

subjects in the study. DNA was extracted from these samples using standard methodology

and thousands of single nucleotide polymorphism (SNP) markers across the genome were

genotyped in each sample.

10   The following standard methods were used for statistical analysis:

       • Differences in SNP genotype and allele frequencies between cases & controls

       • ANOVA of differences in max ALAT and AUC between SNP genotype groups

       • Logistic regression analysis of haplotype frequencies between cases & controls

       • Standard regression analysis of differences in max ALAT and AUC between

15   haplotypes

       The association results for each gene were summarised into a single statistic, p_min,

which is simply the minimum p-value across all of the analyses for the gene. SNPs were

ranked in terms of lowest p value.

       The lowest P value obtained (7.5 x 10^{-6}) was for SNP rs2858869, located in non-coding

20   DNA in the 5' flanking region of DRB1. Hence, genotyping of DRB1, which was known

to be highly polymorphic, was performed using standard methodology. In subsequent

experiments other markers close to DRB1 were genotyped, including the DQA1 gene and

SNPs rs17426385 and rs9275141.

Table 1. Details of DRB1*07 and genetic markers that predict the presence of DRB1*07

Gene or SNP id (HUGO name or rs number)	P_min	5' flank	SNP	3' flank	Allele associated with elevated ALAT	position	D' with DRB1*07
HLA-DRB1	9.1 x 10^{-6}	N/a	N/a	N/a	DRB1*07	SEQ01	-
HLA-DQA1	1.0 x 10^{-5}	N/a	N/a	N/a	DQA1*02	SEQ02	0.98
2858869	7.5 x 10^{-6}	AGACT GATAG	A/G	GACAT AATGC	G	101 of SEQ03	0.85
17426385	7.3 x 10^{-8}	CATTT ACTTA	T/C	TACTTT ACCT	C	101 of SEQ04	1.00

-29-

9275141	1.96E-07	GGTGA TAGA	T/G	ACTAC AATCC	G	401 of SEQ05	0.69

HLA DRB1 typing of samples

Typing of the HLA DRB1 locus was performed using the AlleleSEQR DRB1 Typing kit (Atria Genetics, U.S.A.), according to the manufacturer's instructions.

5   Resultant DNA sequence traces were interpreted using Assign-SBT 3.2.7 software (Conexio Genomics). Approximately 30% of samples gave an ambiguous result, due to a number of heterozygous allelic combinations that result in the same sequence trace. These ambiguities were resolved using the AlleleSEQR HLA-DRB1 GSSP kit (Atria Genetics, U.S.A.), which generates hemizygous sequences from heterozygous PCR products. The

10   kit was used according to the manufacturer's instructions. A DRB1 genotype was assigned to all samples tested.

Results

DRB1*07 was found in 47% of cases and 17% of controls tested.

15   ## Table 2. Distribution of DRB1*07 in cases and controls

DRB1 genotype*	0,0	1,0	1,1
Cases	39 (53%)	32 (43%)	3 (4%)
Controls	108 (83%)	22 (17%)	0 (0%)

* where 1 = DRB1*07

0 = any other DRB1 allele

20

These results show a highly significant association between DRB1*07 and raised ALAT levels ($p=9.1 \times 10^{-6}$, Fisher's exact test). Performing the analysis with high-resolution (specific) alleles did not improve the significance of the analysis, which then showed highly significant association between DRB1*0701 and raised ALAT levels ($p=4 \times 10^{-5}$).

25   An analysis of DRB1 alleles versus maximum ALAT in the cases and controls (combined) demonstrated a highly significant association with an overall p-value $p< 0.0001$ (Fig 1).

-30-

<u>Genotyping of HLA DQA1:</u>

Typing of DQA1 was performed using SSP typing (Dynal AllSet+™ SSP kit). DQA1*02 was found in 48% of cases and 18% of controls tested.

5   Table 3. Distribution of DQA1*02 in cases and controls

DQA1 genotype*	0,0	1,0	1,1
Cases	38 (51%)	33 (45%)	3 (4%)
Controls	107 (82%)	23 (18%)	0 (0%)

* where 1 = DQA1*02

0 = any other DQA1 allele

10

These results show a highly significant association between DQA1*02 and raised ALAT levels (p=1.0 x 10^{-5}, Fisher's exact test).

Example 2.

15   An additional 10 subjects, treated with ximelagatran, who had a transient increase of ALAT >4x ULN and thereafter returned to the baseline level at any time period during days 45-160 of treatment (cases) were compared with 16 subjects (controls) selected from the same studies but without ALAT increase during this period. None of these subjects had been included in the genetic analysis described in Example 1, and they were all from

20   centres in Sweden (i.e. a genetically homogeneous population). Case-control status was used as the variable for statistical analysis and genetic markers that had been significantly associated in Example 1 were tested for replication (1-sided exact test). The results are shown in Table 4.

25

-31-

Table 4: Test for replication of the association between DRB1*07 and markers in linkage
disequilibrium with DRB1*07 and elevated ALAT

SNP (rs)/ allele ID	P_min (case control) in EXAMPLE 1	P_min (case control) in Example 2
DRB1*07	9.11E-06	0.00597
DQA1*02	1.30E-05	0.00597
2858869	4.29E-04	0.0133
17426385	1.02E-07	0.000168
9275141	1.96E-07	0.353

5   Table 4 shows that, even in such a small sample set, the association between

DRB1*07 and elevated ALAT following ximelagatran treatment was significantly

replicated. The association between elevated ALAT and three markers in linkage

disequilibrium with DRB1*07 (DQA1*02, rs 2858869 and rs 17426385) was also

significantly replicated and with the same risk allele as in the original study. The

10   replication of association between elevated ALAT and rs9275141 was not statistically

significant, but this may have been due to the small sample set available for study.

           In conclusion, these results suggest that determination of an individual's carrier

status for the DR7, DRB1*07 or DRB1*0701 alleles can be used to predict the likelihood

15   that an individual will be a case (transient increase of ALAT ≥3x ULN). Hence, a test that

determined the carrier status of an individual for the DR7, DRB1*07 or DRB1*0701

alleles could be used to optimise the suitability of an individual for ximelagatran treatment

with a positive predictive value of 61% and a negative predictive value of 73%, based on

available data.

20   The determination of the presence of the sequence according to SEQ ID NO: 2

(DQA1*02 allele), or whether the individual has a G nucleotide at rs2858869, a C

nucleotide at rs17426385 or a G nucleotide at rs9275141 (positions 101, 101 or 401 of

SEQ03, SEQ04 or SEQ05, respectively), could also be used to optimise the benefit: risk

ratio of an individual for ximelagatran treatment (alleles of DQA1*02, rs2858869,

25   rs17426385, or rs9275141 are in linkage disequilibrium with DRB1*07 with D' of >0.68).

-32-

In a particular embodiment the polymorphism is in linkage disequilibrium with a
D'>0.8. In a further particular embodiment the polymorphism is in linkage disequilibrium
with a D'>0.9.

5

-33-

<u>Claims</u>:

1.   A method of diagnosis comprising:

5   a) providing a biological sample from a human identified as being in need of treatment

with ximelagatran, wherein the sample contains a nucleic acid encoding DRB1 gene;

b) testing the nucleic acid for the presence, on at least one allele, of either

i) HLA-DRB1*07 (SEQ ID NO: 1, or a sequence with up to 4 encoded amino acid

differences provided the encoded allele retains the same antigenic or binding specificity

10   or function as that encoded by SEQ ID NO: 1, or DR7)

ii) an allele of a polymorphism in linkage disequilibrium with a D'>0.68 with (i); and

c) if either (i) or (ii) is found in at least one allele, diagnosing the human as being in the

high risk category of having raised ALAT levels after treatment with the ximelagatran.

15   2.   The method as claimed in claim 1, wherein the allele of a polymorphism in linkage

disequilibrium with a D'>0.68 with (i) is selected from: SEQ ID NO: 2 (DQA1*02 allele),

A>G at position 101 of SEQ ID NO: 3, T>C at position 101 of SEQ ID NO: 4, T>G at

position 401 of SEQ ID NO:5.

20   3.   The method as claimed in claims 1 or 2, wherein if in (c) (i) or (ii) is not found in at

least one allele the human is diagnosed as being in the low risk category of having raised

ALAT levels after treatment with the ximelagatran.

4.   A method for sub-typing a human individual according to their risk status of

25   experiencing elevated ALAT following ximelagatran administration comprising the steps

of:

c)   treating nucleic acid from a sample that has been removed from the individual so as

to identify the alleles present at one or more of the DRB1 gene polymorphisms

selected from the group consisting of DRB1*07 (or DR7), DQA1*02, rs2858869,

30   rs17426385 and rs9275141

d)   assigning the individual to a particular sub-type based on likelihood of

experiencing elevated ALAT following ximelagatran administration, according to

the nucleotide(s) detected in step a).

-34-

5.   The method as claimed in claim 4, wherein the presence, on at least one allele, of
DRB1*07 (or DR7), or DQA1*02, or a G nucleotide at rs2858869, or a C nucleotide at
rs17426385, or a G nucleotide at rs9275141, puts that individual into a high risk sub-type
5   of experiencing elevated ALAT following ximelagatran administration.

6.   The method as claimed in claim 4, wherein the absence, on both alleles, of
DRB1*07 (or DR7), or DQA1*02, or a G nucleotide at rs2858869, or a C nucleotide at
rs17426385, or a G nucleotide at rs9275141, puts that individual into a low risk sub-type of
10   experiencing elevated ALAT following ximelagatran administration

7.   The use of polymorphisms in the human DRB1 gene in the identification of an
individual's risk to experience certain pharmacological effects when being treated with
ximelagatran.
15

8.   The use as claimed in claim 7, wherein the pharmacological effect is elevated
ALAT levels.

9.   The use of an "elevated ALAT susceptibility marker" selected from the group
20   consisting of markers: DRB1*07 (or DR7), or DQA1*02, rs2858869, rs17426385 or
rs9275141, as a tool for the prediction of elevated ALAT following ximelagatran
administration to an individual.

10.   The use of an "elevated ALAT susceptibility haplotype" selected from a haplotype
25   of DRB1*07 (or DR7) or DQA1*02, a G nucleotide at rs2858869, a C nucleotide at
rs17426385 or a G nucleotide at rs9275141, as a tool for the prediction of elevated ALAT
following ximelagatran administration to an individual.

11.   An in vitro diagnostic kit for screening for a genetic predisposition to elevated
30   ALAT levels following ximelagatran administration, which kit comprises components for

-35-

determining the identity of the alleles present in or at one or more of: DRB1, DQA1,

rs2858869, rs17426385 and rs9275141 in the human DRB1 gene region.

12.   The kit as claimed in claim 11, wherein the kit components include allele-specific

amplification primers or allele-specific hybridisation probes capable of determining the

identity of the nucleotide bases at the polymorphic locations.

13. The kit as claimed in claim 11, wherein the kit components include allele-specific

immunological reagents and amplification primers or allele-specific hybridisation probes

capable of determining the identity of the alleles at the polymorphic locations.

14.   A method of treatment comprising:

(a)   selecting a patient in need of anti-thrombotic treatment, the patient's

genome having been identified as corresponding to DRB1*07 alleles (according to

SEQ ID NO: 1), or an allele in linkage disequilibrium with D'>0.68 therewith, on at

least one chromosomal copy; and

(b)   treating the patient with a compound that inhibits or blocks thrombin.

15.   The method as claimed in claim 14, wherein in step (b) the patient is treated with

ximelagatran.

16.   A method of treating a human in need of treatment with the drug ximelagatran,

which method comprises:

i)   determining the absence of DRB1*07 alleles in the human DRB1 gene, or an

allele in linkage disequilibrium with D'>0.68 therewith,

ii)   determining the status of the human by reference to the alleles present in (i);

and,

iii)   administering an effective amount of the drug.

17.   The method as claimed in claim 16, wherein the allele in linkage disequilibrium

with DRB1*07 is selected from: DQA1*02, rs2858869, rs17426385 and rs9275141.

-36-

18.   Use of ximelagatran in the manufacture of a medicament for treating patients in
need of anti-thrombotic treatment, whose DRB1 alleles do not include a DRB1*07 allele
(according to SEQ ID NO: 1), or an allele in linkage disequilibrium with D'>0.68
5   therewith.

19.   The use as claimed in claim 18, wherein the allele in linkage disequilibrium with a
D'>0.68 is selected from the group consisting of: DQA1*02, a G nucleotide at rs2858869,
a C nucleotide at rs17426385, and a G nucleotide at rs9275141.

10

BoxPlot Of MaxALAT v DRB*0701


Figure 1

-1-

SEQUENCE LISTING

<110> AstraZeneca AB

<120> Method

<130> 101973

<140> GB 0520235.3
<141> 2005-10-05

<160> 5

<170> PatentIn version 3.2

<210> 1
<211> 1146
<212> DNA
<213> Homo Sapiens

<400> 1

```
ctggtcctgt cctgttctcc agcatggtgt gtctgaagct ccctggaggc tcctgcatgg      60

cagctctgac agtgacactg atggtgctga gctccccact ggctttggct ggggacaccc     120

aaccacgttt cctgtggcag ggtaagtata agtgtcattt cttcaacggg acggagcggg     180

tgcagttcct ggaaagactc ttctataacc aggaggagtt cgtgcgcttc gacagcgacg     240

tgggggagta ccgggcggtg acggagctag ggcggcctgt cgccgagtcc tggaacagcc     300

agaaggacat cctggaggac aggcggggcc aggtggacac cgtgtgcaga cacaactacg     360

gggttggtga gagcttcaca gtgcagcggc gagtccatcc tgaggtgact gtgtatcctg     420

ccaagactca gcccctgcag caccacaacc tcctggtctg ctctgtgagt ggtttctatc     480

caggcagcat tgaagtcagg tggttccgga acggccagga agagaaggct ggggtggtgt     540

ccacaggcct gatccagaat ggagactgga ccttccagac cctggtgatg ctggaaacag     600

ttcctcggag tggagaagtt tacacctgcc aagtggagca cccaagtgtg atgagccctc     660

tcacagtgga atggagagca cggtctgaat ctgcacagag caagatgctg agtggtgtcg     720

ggggctttgt gctgggcctc ctcttccttg gggccgggtt gttcatctac ttcaggaatc     780

agaaaggaca ctctggactt cagccaacag gattcctgag ctgaagtgaa gatgaccaca     840

ttcaaggaaa aaccttctgc cccagctttg caggatgaaa cacttcccgc ttggctctca     900

ttcttccaca agagagacct ttctccggac ctggttgcta ctggttcagc aactgcagaa     960

aatgtcctcc cctgtggctg cctcagctca tgcctttggc ctgaagtccc agcattgatg    1020

gcagccctc atcttccaag ttttgtgctc ccctttacct aacgcttcct gcctcccatg    1080

catctgtact cctcctgtgc cacaaacaca ttacattatt aaatgtttct caaacatgga   1140

gttaaa                                                             1146
```

<210> 2
<211> 2326
<212> DNA
<213> Homo Sapiens

<400> 2

```
agccagtcct gagaggaaag gaagtataat caatttgtta ttaactgatg aaagaattaa      60

gtgaaagata aaccttagga agcagaggga agttaatcta tgactaagaa agttaagtac     120
```

-2-

```
tctgataact cattcattcc ttcttctgtt catttacatt atttaatcac aagtccatga    180

tgtgccaggc actcaggaaa tagtgaaaat cggacacgcg atattctgcc cttgtgtagc    240

acacactgta gtgggaaaga aagtgcactt ttaactggac aactatcaac acgaagaggg    300

gaggaagcag gggctggaaa tgtccacaga ctttgccaaa gacaaagccc ataatatttg    360

aaagtcagtt tcttccatca ttttgtgtat taaggttttt tattctcctg ttctctgcct    420

tcctgcttgt catcttcact catcagctga ccacgttgcc tcttacggtg taaacttgta    480

ccagtcttac ggtccctctg gccagttcac ccatgaattt gatggagacg aggagttcta    540

tgtggacctg gagaggaagg agactgtctg gaagttgcct ctgttccaca gacttagatt    600

tgacccgcaa tttgcactga caaacatcgc tgtgctaaaa cataacttga acatcctgat    660

taaacgctcc aactctaccg ctgctaccaa tggtatgtgt ccaccattct gcctttcttt    720

actgatctat ccctttatac caagtttcat tattttcttt ccaagaggtc cccagatctt    780

ctcatggcaa ttgctgaaat tttatcattt ctcatctcta aaatcacata tccccatgta    840

atacaagggt ctttccatta tgcattcatt aaatcattct aggagaggtc tcatcaacct    900

cctactttat taaacatgcc cacagagaga agggcacagg agtaaagcag aggcaatgtg    960

tcattgctcc caagtagaag gtaaataagg cctctttgac cagcaggaga ggaaatgctg   1020

gtaggaagac tcttccagga tgtaatgcag aagctcaggg cagagctatt cacacttcac   1080

accagtgctg tttcctcacc atagaggttc ctgaggtcac agtgttttcc aagtctcccg   1140

tgacactggg tcagcccaac accctcatct gtcttgtgga caacatcttt cctcctgtgg   1200

tcaacatcac ctggctgagc aatgggcact cagtcacaga aggtgtttct gagaccagct   1260

tcctctccaa gagtgatcat tccttcttca agatcagtta cctcaccttc ctcccttctg   1320

ctgatgagat ttatgactgc aaggtggagc actgggggcct ggatgagcct cttctgaaac   1380

actggggtaa ggatgagttt caccattttt tgatgctttc ttgtctgtca agttcagaac   1440

ttcctgcctt ttactctatg tcccaaaact tgttttccac acttcatgag tttctttat    1500

cttttttttt tttgaaagaa ttaagcaaca aaagcacaga tttattaaaa aagaaagtac   1560

actccacagg gtgggagcag gcctgccact tcatgggttt ctaataacag acttcactct   1620

cctccctgag ccaggggcct tgagtctttg cagagccaac cctccacccc atcccatccc   1680

tcacacatgc acatgagcac actctgcatt ctgacctcaa caacttcact tccacagagc   1740

ctgagattcc agcacctatg tcagagctca cagagactgt ggtctgtgcc ctggggttgt   1800

ctgtgggcct cgtgggcatt gtggtgggga ccgtcttgat catccgaggc ctgcgttcag   1860

ttggtgcttc cagacaccaa gggcccttgt gaatcccatc ctgaaaaaga aggtaagttt   1920

gagatttgtt agagctgaag ctgcaggaag aaagtgggga ggaggctgtg gacatgaatg   1980

tggttgaaag ttgtagggga attgggaagt ggcatgatga tgacacagga gcccccttgg   2040

acccatcgat ctcatgtctg tcctgttgca ggtgcatcac catctacagc agcggaagag   2100

tggacttgct acatgaccta gcactattct ctggcccgat ttatcatacc cttttctcc    2160

tgcaaatgtt tctcctctta cctttctct  gctttttttt ccttaagctt ctgtatcccc   2220

tcagagctca caaatgcctt tgaattcttt ccctgacctc ctgattttt  tttctttttct   2280
```

-3-

caggtgttac ctactaagag atgcctgggg taagccgccc agctac   2326

<210>   3
<211>   240
<212>   DNA
<213>   Homo Sapiens

<400>   3
aattaggaca tgacataggt ggttagcaaa taaagaatat ttgcagagta aagcaaaatg   60

tgcagtgagg attggaggag ctgggcattt agactgatag agacataatg cctggttttc   120

cattcctgtg cctggatagt attaaaagca caaataaaaa gctatcctgc tgctatctgc   180

ctgctattca tattatagaa gagatggaga ctgtcagaga gatctattat gccaactctg   240

<210>   4
<211>   201
<212>   DNA
<213>   Homo Sapiens

<400>   4
attaatttat gaagagaacc ttttctcttt ctactagaca aaggtaacaa attagctttt   60

gttaaaatgg catactgttc ttctgagttt catttactta ctactttacc ttacattaaa   120

attatgacct gaagacagaa ggaactggaa caatgttcac tgtgttatgg ccggatgaag   180

caggaagagg agaagagaca a   201

<210>   5
<211>   801
<212>   DNA
<213>   Homo Sapiens

<400>   5
cccctaaagc tcaagaaagt tgtctgggat atacaaagta ctgactacac caattattat   60

atcatgatct aaagtgtaag tcacaagtca aactcttgat cacttcattc atattacatg   120

ttccagatta taaccactgg aaaacttctc taacagtaat tttgcatgaa ctcatgtgtt   180

ctaaaactac aaccaagtgt gcattcttc ctgataggca tttaacacac taagtgacca   240

tatgacttaa attgtccata tgatgctgag agttataaga ttcatagact cttaagtttg   300

ggcataccaa ccacaatcca tcatgcaatt aaagcagtac atttgaaacc agacttcagc   360

aggtttaaaa actaggtggt tgtctggtt tggtgataga gactacaatc ccagaagggt   420

ttatgctctt gtttatcttc tccttgatgg agtataattg ttttagtgtc tactgaattt   480

tcatctaatt tggtcttgag gtctctctca tgagaacagc tataaactag ttttgctctg   540

ctggagcttt agggaatttg ggtgtggagt ttacaatgta tcttcatggg atgcttcttt   600

attctggaag atggtctaat gcctaagtgt ctgacctgta accaagcgcc cctctcacag   660

gaaacttgtt tatactggaa gacacttttg tggctcttgt ctgacctgtg tccagtttat   720

tcctgccaaa atttcactct ctgggacagc tctgtctggg aaagaagtta aatttgaagg   780

tgtcaggtaa gatagaaaga a   801

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
INV. C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE DBSNP [Online] NCBI; 21 August 2004 (2004-08-21), PERLEGEN: XP002413997 retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV/SNP Database accession no. ss24651601 the whole document —/—	11-13

[X] Further documents are listed in the continuation of Box C.   [ ] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
24 January 2007	07/02/2007

| Name and mailing address of the ISA/
 European Patent Office, P.B. 5818 Patentlaan 2
 NL – 2280 HV Rijswijk
 Tel. (+31–70) 340–2040, Tx. 31 651 epo nl,
 Fax: (+31–70) 340–3016 | Authorized officer

 Werner, Andreas |

C(Continuation).   DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BRIGHTON TIMOTHY A: "The direct thrombin inhibitor melagatran/ximelagatran." THE MEDICAL JOURNAL OF AUSTRALIA. 18 OCT 2004, vol. 181, no. 8, 18 October 2004 (2004-10-18), pages 432-437, XP002409201 ISSN: 0025-729X the whole document page 436, column 2, paragraph 3	18,19
A	VOORA DEEPAK ET AL: "The pharmacogenetics of coumarin therapy." PHARMACOGENOMICS, vol. 6, no. 5, July 2005 (2005-07), pages 503-513, XP009076848 ISSN: 1462-2416 page 509, column 2, line 33 - line 38	1-19
A	PETERSEN PALLE ET AL: "Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II: A dose-guiding, tolerability, and safety study." JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 41, no. 9, 7 May 2003 (2003-05-07), pages 1445-1451, XP002413775 ISSN: 0735-1097 the whole document	1-19

FURTHER INFORMATION CONTINUED FROM   PCT/ISA/ 210

Continuation of Box II.1

Claims 1-3 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT, as the provision of a biological sample is considered to encompass a step of surgery of the human body.

For the assessment of the present claims 14-17 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of claims 1-3 and 14-17 (Art. 34(4)(a)(i) PCT).

INTERNATIONAL SEARCH REPORT

Box II   Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:   1-3, 14-17 (with respect to industrial application)
     because they relate to subject matter not required to be searched by this Authority, namely:

    see FURTHER INFORMATION sheet PCT/ISA/210

2. [ ] Claims Nos.:
     because they relate to parts of the International Application that do not comply with the prescribed requirements to such
     an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
     because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III   Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all
     searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
     of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report
     covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
     restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest   [ ] The additional search fees were accompanied by the applicant's protest.

                               [ ] No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2004)